The word ADHD highlighted in pink

dafabet sports betting

How N.J. company, Tris Pharma, is working to solve severe shortage of ADHD medication Tris Pharma External Link icon

A year-long shortage of ADHD medicine has created dafabet live dealer gamean endless loop of millions of parents searching desperately to find medication for their kids — often on a monthly basis. Monmouth Junction-based Tris Pharma is working to help.

Image showing different pain conditions in human

Clinical Trials Arena

Pain points: Unsolved recruitment and trial design issues in pain clinical trials Tris Pharma External Link icon

Although pain affects millions of people worldwide, the industry is still struggling in the ongoing search for safe and effective medication.

Ketan Mehta, founder and CEO of Tris Pharma

The Bio Report

Managing Pain without Addiction Tris Pharma External Link icon

Opioid overdose, abuse, and addiction affect an estimated 3 million Americans and accounts for $35 billion in U.S. healthcare costs every year. Tris Pharma is developing dafabet casino appthe opioid Cebranopadol, as an effective pain management therapy without the addictive potential of FDA-approved opioids.

Ketan Mehta, founder and CEO of Tris Pharma

Life Science Leader

To America, A New Biopharma Model Tris Pharma External Link icon

Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses-platform technology licensing, generic medicines, and new drug development.

Image of human head

SLEEP REVIEW

How to Navigate the Narcolepsy Pharmacotherapy LandscapeManaging Pain without Addiction Tris Pharma External Link icon

With new narcolepsy drugs available, sleep specialists face the challenge of dafabet live casinoselecting the most suitable therapies for their patients.

Ketan Mehta, founder and CEO of Tris Pharma talking in interview
NJBIZ Conversations: Ketan Mehta Tris Pharma External Link icon

Tris Pharma founder and CEO Ketan Mehta talks about his company’s work on a new, non-addictive pain treatment and other promising products in the pipeline.

Image of white tablets

PharmaVoice

Is America ready for a new kind of opioid? Tris Pharma External Link icon

Tris Pharma’s CEO is “betting the company” on a pain reliever with the power of an opioid and a lower chance of addiction.

Image of person with pain

BioBuzz

Flying Under the Radar, Tris Pharma Builds Strong Pipeline in ADHD, Pain, Neurological Disorders Tris Pharma External Link icon

In the continual wake of the opioid crisis gripping the nation, New Jersey-based Tris Pharma is developing a pipeline of pain treatments dafabet casino appthat are expected to be much safer than currently available products.